TC BIOPHARM HOLDINGS PLC-ADR (TCBP) Stock Price, Forecast & Analysis
NASDAQ:TCBP • US87807D6085
TCBP Key Statistics, Chart & Performance
The current stock price of TCBP is 0.5 USD. In the past month the price decreased by -80%. In the past year, price decreased by -99.79%.
TCBP Technical Analysis
TCBP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to TCBP. TCBP may be in some trouble as it scores bad on both profitability and health.
TCBP Financial Highlights
Over the last trailing twelve months TCBP reported a non-GAAP Earnings per Share(EPS) of -4.21. The EPS decreased by -27216.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -71.77% | ||
| ROE | -293.88% | ||
| Debt/Equity | 1.07 |
TCBP Forecast & Estimates
7 analysts have analysed TCBP and the average price target is 48.96 USD. This implies a price increase of 9692% is expected in the next year compared to the current price of 0.5.
For the next year, analysts expect an EPS growth of 96.52% and a revenue growth -100% for TCBP
TCBP Ownership
TCBP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.59 | 411.552B | ||
| AMGN | AMGEN INC | 16.79 | 201.047B | ||
| GILD | GILEAD SCIENCES INC | 17.19 | 192.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.3 | 121.106B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.03 | 83.892B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.55 | 43.941B | ||
| INSM | INSMED INC | N/A | 32.101B | ||
| NTRA | NATERA INC | N/A | 29.393B | ||
| BIIB | BIOGEN INC | 12.83 | 28.709B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.24 | 20.773B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCBP
Company Profile
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
Company Info
TC BIOPHARM HOLDINGS PLC-ADR
Maxim 1, 2 Parklands Way, Holytown
Motherwell GB
Employees: 41
Phone: 441414337557
TC BIOPHARM HOLDINGS PLC-ADR / TCBP FAQ
What does TCBP do?
TC Biopharm (Holdings) Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel immunotherapy products based on its proprietary allogeneic gamma delta T cell platform. The company employs 41 full-time employees The company went IPO on 2022-02-23. The firm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line - phase IIb/III pivotal trial in treatment of acute myeloid leukemia using its proprietary allogeneic CryoTC technology to provide frozen product to clinics worldwide. Its lead product is TCB-008. In addition to unmodified allogenic GD-Ts for treatment of blood cancers, the Company is also developing an expanded platform for TCB-008 use case in anti-fungal, anti-viral and anti-microbial diseases. Its unmodified cell therapy, used in the treatment of acute myeloid leukemia, is supplied under the name OmnImmune. The company is also developing a range of genetically modified CAR-T products for the treatment of solid cancers.
What is the stock price of TC BIOPHARM HOLDINGS PLC-ADR today?
The current stock price of TCBP is 0.5 USD. The price decreased by -67.53% in the last trading session.
What is the dividend status of TC BIOPHARM HOLDINGS PLC-ADR?
TCBP does not pay a dividend.
How is the ChartMill rating for TC BIOPHARM HOLDINGS PLC-ADR?
TCBP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists TCBP stock?
TCBP stock is listed on the Nasdaq exchange.
What is the GICS sector and industry of TCBP stock?
TC BIOPHARM HOLDINGS PLC-ADR (TCBP) operates in the Health Care sector and the Biotechnology industry.
What is the ownership structure of TC BIOPHARM HOLDINGS PLC-ADR (TCBP)?
You can find the ownership structure of TC BIOPHARM HOLDINGS PLC-ADR (TCBP) on the Ownership tab.